The Last Bidder

A $4.1 billion buyout, a captive that is negative $10.8 billion without its permission slip, and the one bidder who didn't mind.

Twenty interested firms were invited to look at Brighthouse Financial for purchase. Sixteen signed confidentiality agreements and were let into the data room, where the company kept the numbers the public never sees, including an actuarial appraisal of what the business is actually worth. Ten came back with bids. Six of those were offers for the whole company, between $2.7 billion and $4.6 billion.

The winning bidder is called Aquarian.

The highest bid did not come from Aquarian. A firm the proxy calls Party A offered $4.6 billion, $78.57 a share, more than half a billion above the winning price. Its offer required a reinsurer to stand beside it at closing and take, in the proxy’s words, “the majority of the biometric and market risk from the Company’s legacy businesses,” to provide surplus relief for redundant reserves, cash flow swaps on liabilities, and coinsurance on the term book. Party A told the board plainly that it would not be required to fund and close unless the reinsurance closed with it. The reinsurer studied the risk for months and could not get there. In July 2025, Party A withdrew.

Party D’s offer was conditioned on permission to set up new captive reinsurers, onshore and offshore, to absorb the legacy liabilities. The board said no to that in the first round of negotiations. Party C, a life insurance group that presumably knows what a reserve is, revised its number once its reinsurance assumptions moved. Its second-round price was a measly $40.00 a share. The proxy prints that without comment.

Every informed buyer priced Brighthouse on the condition that somebody else absorb what is inside it.

❧ ❧ ❧

Aquarian was founded in 2017 by Rudy Sahay. His biography says that before his current role, he was a founding member of the Principal Investment group at Guggenheim Partners, where he “completed over $3 billion in private equity transactions, almost all in the insurance industry,” and “was involved with the creation, acquisition or oversight of six different insurance companies, managing in excess of $100 billion in assets,” and worked on “structuring investments for the insurance company balance sheets to maximize capital efficiency.” The biography does not name the six companies, but it doesn’t have to. The insurance platform Guggenheim’s principal-investment arm created, acquired and oversaw in those years consisted of Security Benefit, Guggenheim Life and Annuity (now called Clear Spring), EquiTrust and Delaware Life. From Guggenheim, Sahay went to Cain Hoy, the investment firm Todd Boehly co-founded on his way out of Guggenheim.

The chief executive of Aquarian’s insurance arm is John Frye. Before Aquarian, he was the chief financial officer of Security Benefit and its life insurance subsidiaries.

The money is newer than the executives. Aquarian’s equity for this deal runs through an investment commitment from Mubadala Capital, whose majority owner, Goldman Sachs notes in its own conflicts disclosure, is the government of Abu Dhabi. The parties have made a filing with CFIUS, the national-security committee, about the Abu Dhabi financing. The filing is voluntary and its approval is not a condition of the deal.

❧ ❧ ❧

What did the fifteen see in the data room?

Brighthouse Life Insurance Company, the Delaware operating company, reports $189.2 billion of liabilities and $3.6 billion of surplus. That is 1.9 cents of cushion per present value of promises; the national average runs about seven. It has lost money on a statutory basis three years running, $6.2 billion in total, and its unassigned surplus is now negative, which means that in 2026 it cannot pay its parent an ordinary dividend. Whatever the new owner takes out of this company, a Delaware regulator will have to approve. The same Delaware regulator answering questions from prosecutors about Delaware Life, Clear Spring, and Egan Jones ratings. The same Delaware Regulator, Trinidad Navarro, that litigated to protect captive secrecy all the way up to the Supreme Court.

The balance sheet balances because of a subsidiary. Brighthouse Life has ceded $24.4 billion of reserves to Brighthouse Reinsurance Company of Delaware, its wholly owned captive, whose financial statements are confidential by state law. The statutory filings show roughly $2.1 billion ceded the year before the spin, $8.2 billion by the end of 2016, $18.5 billion by the end of 2017, once the spin was done, and $24.3 billion now. The filings also show what stands behind the credit the insurer takes for it: $5.2 billion of funds withheld. Brighthouse Life owns eight million shares of the captive that owes it $24 billion, and carries them on its books at $0.

The captive reports $678 million of capital. It reports that number because Delaware lets it count, as an admitted asset, $11.5 billion of credit-linked notes on a financing facility it has never drawn, “with the explicit permission of the Delaware Insurance Commissioner,” as the parent’s own annual report puts it. Take the permission slip away and the captive’s capital is roughly negative $10.8 billion. The company’s description of what it ceded there: “redundant, non-economic reinsurance financing support.”

The disclosure was not always this quiet. The captive’s first annual report, for 2017, when the permission was worth $8.3 billion, included a sentence that has not appeared since: “BRCD’s RBC would have triggered a regulatory event without the use of the state prescribed practice.” Without the permission, in other words, the captive fails its capital test and the regulator must act. That sentence disappeared, but the math remained the same. The permission is worth $11.5 billion now. A second change came in 2021, when the words “serving as collateral” quietly left the description of the notes. The facility itself only grew: $10 billion at inception in 2017, $12 billion in June 2020, $15 billion effective the last day of 2022, that increase granted, again, “with the explicit permission of the Delaware Commissioner.” The “pool of highly rated third-party reinsurers” on the other side of it has never been named, and no reinsurer in the SEC’s records has ever disclosed being in it.

The captive has also paid dividends. Each required the Delaware commissioner’s approval, which were approved: $535 million in cash in 2017, $600 million in 2020, $600 million in 2021. The 2021 dividend consisted of $400 million in settlement of affiliated reinsurance balances, $197 million of invested assets, and $3 million of cash. Ed Spehar, the chief financial officer, described those distributions last year as “bringing down the excess -- what we consider to be excess capital at BRCD.” That is the entity whose capital is negative $10.8 billion without the permitted practice.

The money kept moving once it surfaced. Brighthouse Life paid $1.25 billion up toward the holding company in 2020 and $550 million in 2021, both ordinary dividends, both while the captive relief held. Since the spin, the holding company has spent $2.6 billion repurchasing its own stock, retiring more than half its shares, 119.8 million at separation down to 57.2 million. A company that lost $6.2 billion statutorily in three years cut its share count by 52 percent. And in 2025, for the first time, policyholders withdrew more from their accounts than they put in.

Tom Gober, the forensic accountant, has sent the Delaware commissioner three letters about this between April and July. He has asked to testify at the public hearing on the sale. The Capitol Forum published its investigation of the captive’s accounting on August 7; Brighthouse’s stock fell about two percent that day, underneath a seventy-dollar cash bid. As of this writing, no hearing is on the calendar.

❧ ❧ ❧

None of this wandered into Delaware randomly.

In 2001, MetLife set up a reinsurer in Bermuda called Exeter Reassurance and began ceding it the guarantees on variable annuities, the promises that pay out when markets fall. Offshore, the guarantees were backed with derivatives and letters of credit rather than bonds; at the end of 2012 Exeter held $17.6 billion of assets, of which less than two billion were fixed-income securities. In 2011 it moved to the Cayman Islands. Then New York’s regulator started giving speeches about shadow insurance, and MetLife announced it would bring the business home.

It did not bring the business to New York. In October 2013, Exeter re-domesticated to Delaware as a pure captive. In November 2014 it was merged, along with two other subsidiaries, into the old Travelers charter, renamed MetLife Insurance Company USA. The footnote to that transaction is worth quoting exactly. The Delaware Department of Insurance approved two special accounting practices for the new company, and granted it “permission not to calculate, record or disclose the effect of this permitted practice on statutory surplus and net income.” A second permission converted $4.4 billion of the captive’s capital accounts into surplus “in a manner similar to a quasi-reorganization.” Ten months before the merger, the company had surrendered its New York insurance license.

In March 2017 MetLife Insurance Company USA was renamed Brighthouse Life Insurance Company. That August it was spun off to shareholders. Same charter, same statutory ID, same state. Delaware’s captive statute declares that the growth of the captive industry is “in the best interests of this State”; the chapter governing captives like Brighthouse Re promises an authorization process “that is both thorough and swift.” The company was built inside a jurisdiction that advertises.

❧ ❧ ❧

Which brings us back to the one bidder who stayed, and what it actually asked for.

The merger agreement contains a clause defining a “Burdensome Condition.” Aquarian is not obligated to close if regulators, as a price of approval, require capital contributions beyond a business plan that was filed confidentially, or any guaranty from the buyer, or restrict dividends, or cause “a non de minimis and adverse change or modification to, or revocation or termination of, the intercompany reinsurance business operations of BRCD or any permitted or prescribed statutory accounting practice.” One more prong, less noticed: the deal also dies if regulators “restrict or limit in any non de minimis manner or prohibit the investment management activities of Parent” or its affiliates. The fee pipe is a protected term of the contract.

So the conditions of the purchase are: no new capital beyond the secret plan, no guarantees, no dividend restrictions, no change to the captive, no change to the accounting, and no limits on the buyer managing the money. In exchange, $70.00 a share in cash to the shareholders. The company itself receives nothing. Goldman’s fairness analysis, buried in the proxy, valued the business standalone at $30.40 to $52.57 a share on dividends it could actually distribute, and noted that management’s own projections through 2027 “did not project any dividend distributions” at all.

If the approvals have not arrived by September 6, the agreement extends itself to December 6. Delaware, New York and Massachusetts each hold a piece of the decision, and they do not hold equal risk. The Capitol Forum, analyzing the New York affiliate’s statutory filings, found that New York’s regulator required Brighthouse Life to set aside $3.76 billion in trust for the New York company’s benefit, more than covering the $3.11 billion of New York liabilities it assumed. New York’s policyholders are largely walled off from whatever happens to Brighthouse Life and its captive. No one built that wall for policyholders anywhere else. Two million annuity contracts and insurance policies ride on the decision, and something newer does too: Brighthouse is one of two insurers issuing the annuities inside BlackRock’s LifePath Paycheck, the guaranteed-income product now being installed as the default option in 401(k) plans covering roughly half a million workers, most of whom have never chosen Brighthouse and many of whom have never heard of it.

Aquarian already owns an insurance company, a small Kentucky annuity writer called Investors Heritage. On August 7, the same day the Capitol Forum piece ran, the rating agency AM Best revised its outlook on Investors Heritage to negative, citing, among other things, its “greater exposure to private credit assets.”

Sixteen firms read the real numbers. Fourteen walked away or asked someone else to hold the risk. One repriced the equity at forty dollars. The last bidder asked for one thing above all, written into the contract: that Delaware keep counting the way it agreed to count when the captive came ashore.

There is a high-conviction trade around this. The note on it is below, for paid subscribers.

❧ ❧ ❧

Sources: The bid chronology, the Burdensome Condition, the fairness analyses and the projections are from Brighthouse’s definitive merger proxy; the surplus, reserve-credit and captive figures are from Brighthouse’s SEC filings, its earnings-call transcripts, and Brighthouse Life’s 2025 statutory annual statement as excerpted in Tom Gober’s letters to the Delaware commissioner, which he has said he will share publicly; the captive’s dividend history, the vanished RBC sentence and the facility expansions are from the 2017 through 2025 annual reports read in sequence; The Capitol Forum’s August 7 report first brought the Delaware fight to a wider audience; Sahay’s history is from Somerset Re’s 2025 financial condition report; the Exeter Reassurance history and the 2014 permitted-practice language are from MetLife Insurance Company USA’s Form 10-K filings; the Delaware statutory language is from 18 Del. C. §§6901 and 6951. The identification of the six insurers in Sahay’s biography with the Guggenheim-era platform is an inference from the era and the platform’s composition; the biography itself does not name them. Aquarian, Brighthouse and the Delaware Department of Insurance have not been accused by any regulator of wrongdoing, and permitted practices are, by definition, permitted.